Cargando…
Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study
AALL1931, a phase 2/3 study conducted in collaboration with the Children’s Oncology Group, investigated the efficacy and safety of JZP458 (asparaginase erwinia chrysanthemi [recombinant]-rywn), a recombinant Erwinia asparaginase derived from a novel expression platform, in patients with acute lympho...
Autores principales: | Maese, Luke, Loh, Mignon L., Choi, Mi Rim, Lin, Tong, Aoki, Etsuko, Zanette, Michelle, Agarwal, Shirali, Iannone, Robert, Silverman, Jeffrey A., Silverman, Lewis B., Raetz, Elizabeth A., Rau, Rachel E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651770/ https://www.ncbi.nlm.nih.gov/pubmed/36108304 http://dx.doi.org/10.1182/blood.2022016923 |
Ejemplares similares
-
Population pharmacokinetics of intramuscular recombinant Erwinia chrysanthemi asparaginase (JZP458) in patients with acute lymphoblastic leukemia
por: Lin, Tong, et al.
Publicado: (2023) -
Population Pharmacokinetic Model Development and Simulation for Recombinant Erwinia Asparaginase Produced in Pseudomonas fluorescens (JZP‐458)
por: Lin, Tong, et al.
Publicado: (2021) -
A Randomized Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant Erwinia Asparaginase (JZP‐458) in Healthy Adult Volunteers
por: Lin, Tong, et al.
Publicado: (2021) -
Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
por: Maese, Luke, et al.
Publicado: (2022) -
SARS‐CoV‐2 infections in patients enrolled on the Children's Oncology Group standard‐risk B‐cell acute lymphoblastic leukemia trial, AALL1731
por: Elgarten, Caitlin W., et al.
Publicado: (2023)